TNF and rheumatoid arthritis: As expected, ADAb+ was significantly associated with reduced anti-TNF response to RA at all the time points after follow-up (3 months: OR = 0.03, 95% CI: 0.01 to 0.13, P < 0.001; 6 months: OR = 0.04, 95% CI: 0.01 to 0.22, P < 0.001; 12 months: OR = 0.26, 95% CI: 0.11 to 0.57, P < 0.001; ≥24 months: OR = 0.16, 95% CI: 0.08 to 0.33, P < 0.001) (Figure 2).